12:19:07 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-19 Bokslutskommuniké 2024
2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-30 Split BGBIO 100:1
2024-05-29 Kvartalsrapport 2024-Q1
2024-05-24 X-dag ordinarie utdelning BGBIO 0.00 NOK
2024-05-23 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-22 Kvartalsrapport 2023-Q1
2023-05-22 Årsstämma 2023
2023-04-21 X-dag ordinarie utdelning BGBIO 0.00 NOK
2023-02-16 Bokslutskommuniké 2022
2022-11-15 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-29 X-dag ordinarie utdelning BGBIO 0.00 NOK
2022-04-28 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2022-01-06 Extra Bolagsstämma 2022
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-22 X-dag ordinarie utdelning BGBIO 0.00 NOK
2021-03-19 Årsstämma 2021
2021-02-10 Bokslutskommuniké 2020
2020-12-09 Extra Bolagsstämma 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-19 Kvartalsrapport 2020-Q1
2020-03-17 X-dag ordinarie utdelning BGBIO 0.00 NOK
2020-03-16 Årsstämma 2020
2020-02-11 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-19 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-14 X-dag ordinarie utdelning BGBIO 0.00 NOK
2019-03-13 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-15 X-dag ordinarie utdelning BGBIO 0.00 NOK
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-14 Årsstämma 2018
2018-03-09 Extra Bolagsstämma 2018
2018-02-13 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-03-23 X-dag ordinarie utdelning BGBIO 0.00 NOK
2017-03-22 Årsstämma 2017
2016-06-22 X-dag ordinarie utdelning BGBIO 0.00 NOK
2016-06-21 Årsstämma 2016
2015-06-23 X-dag ordinarie utdelning BGBIO 0.00 NOK
2015-06-22 Årsstämma 2015

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
BerGenBio är ett norskt onkologibolag. Idag bedriver bolaget forskning och utveckling av hämmande läkemedel för behandling av aggressiva cancertyper. Bolaget har utvecklat ett flertal produkter vars sammansättning ämnar blockera proteinet AXL, ett protein positivt relaterat med spridning av cancercellerna. Bolaget grundades under 2007 och har sitt huvudkontor i Bergen, Norge.
2022-11-21 21:30:00

Bergen, Norway, 21 November 2022 - BerGenBio ASA (the "Company") (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announce that the Board of Directors has granted options to employees.

The annual general meeting in the Company 28 April 2022 approved the share option program and authorised the board of directors of the Company to issue shares to the Company's employees as part of a long-term incentive plan and share option program.

Options granted under the share option program will vest equally over a three-year vesting period following the grant and each option, when exercised, will give the right for each option to acquire one share in the Company at a fixed strike price. Options granted under the share option program expire eight years after grant date.

A total of 2,114,230 share options, equal to 2.38% of total shares issued in the Company, were granted at strike price at NOK 7.59 per option, constituting the volume weighted average share price over the last two weeks before the grant.

The board considers an option program as an important element in attracting and retaining employees to foster long-term success. The board considers the option program terms and allocation to be at the market for comparable peers.

Due to changes in Executive Management over the last two years, this grant is above the average annual grant which has been 1.87% over the last five years. After this grant the total issued options is 4.92% of the total issued shares in the Company, below the average level over the last five years of 5.93%.

Of the total grant the following were granted to primary insiders (total holdings of share options following this grant):

Martin Olin - CEO: 950,000 (950,000)

Rune Skeie - CFO: 100,000 (397,097)

James Barnes - COO: 110,000 (411,522)

Cristina Oliva - CMO: 200,000 (200,000)

Nigel McCracken - CSO: 275,000 (275,000)

In total 1,635,000 share options were granted to primary insiders.

Following this grant a total of 4,358,505 share options are issued, equal to 4.92% of the total shares issued in the Company. Of this, 1,753,726 share options are vested and 2,604,779 not vested.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.